Lala M. Dunbar

1.6k total citations
22 papers, 1.1k citations indexed

About

Lala M. Dunbar is a scholar working on Infectious Diseases, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, Lala M. Dunbar has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 7 papers in Cardiology and Cardiovascular Medicine and 7 papers in Epidemiology. Recurrent topics in Lala M. Dunbar's work include Pneumonia and Respiratory Infections (7 papers), Antimicrobial Resistance in Staphylococcus (7 papers) and Blood Pressure and Hypertension Studies (6 papers). Lala M. Dunbar is often cited by papers focused on Pneumonia and Respiratory Infections (7 papers), Antimicrobial Resistance in Staphylococcus (7 papers) and Blood Pressure and Hypertension Studies (6 papers). Lala M. Dunbar collaborates with scholars based in United States, Sweden and South Africa. Lala M. Dunbar's co-authors include Jim Xiang, Mohammed M. Khashab, Neringa Zadeikis, James B. Kahn, Alan M. Tennenberg, Richard G. Wunderink, Michael P. Habib, Leon G. Smith, Barbara A. Wiesinger and G. Ralph Corey and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and American Heart Journal.

In The Last Decade

Lala M. Dunbar

21 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lala M. Dunbar United States 16 465 396 258 254 176 22 1.1k
Y. Péan France 15 417 0.9× 283 0.7× 327 1.3× 201 0.8× 240 1.4× 38 998
Murray A. Abramson United States 17 384 0.8× 459 1.2× 218 0.8× 295 1.2× 344 2.0× 27 1.9k
Jeannie D. Chan United States 20 267 0.6× 303 0.8× 140 0.5× 149 0.6× 106 0.6× 53 1.1k
Alexandra Heininger Germany 19 681 1.5× 265 0.7× 187 0.7× 148 0.6× 172 1.0× 64 1.4k
Luis Felipe Reyes Colombia 26 849 1.8× 831 2.1× 134 0.5× 429 1.7× 203 1.2× 107 2.0k
Denis Bugnon France 16 351 0.8× 290 0.7× 395 1.5× 179 0.7× 228 1.3× 32 816
Christian Eckmann Germany 22 230 0.5× 482 1.2× 183 0.7× 270 1.1× 188 1.1× 80 1.4k
Daniel Curcio United States 16 436 0.9× 265 0.7× 158 0.6× 81 0.3× 226 1.3× 50 866
Efthymia Giannitsioti Greece 18 523 1.1× 406 1.0× 90 0.3× 94 0.4× 133 0.8× 38 982
Twisha S Patel United States 16 439 0.9× 214 0.5× 257 1.0× 257 1.0× 370 2.1× 59 958

Countries citing papers authored by Lala M. Dunbar

Since Specialization
Citations

This map shows the geographic impact of Lala M. Dunbar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lala M. Dunbar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lala M. Dunbar more than expected).

Fields of papers citing papers by Lala M. Dunbar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lala M. Dunbar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lala M. Dunbar. The network helps show where Lala M. Dunbar may publish in the future.

Co-authorship network of co-authors of Lala M. Dunbar

This figure shows the co-authorship network connecting the top 25 collaborators of Lala M. Dunbar. A scholar is included among the top collaborators of Lala M. Dunbar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lala M. Dunbar. Lala M. Dunbar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sessink, P.J.M., et al.. (2024). Workflow evaluation of environmental contamination with hazardous drugs during compounding and administration in an UK hospital. Journal of Oncology Pharmacy Practice. 32(1). 43–55.
2.
Stryjewski, Martín E., Steven L. Barriere, W. O'Riordan, et al.. (2012). Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy. 67(6). 1496–1502. 19 indexed citations
3.
Peacock, W. Frank, Joseph Varón, Ramin Ebrahimi, Lala M. Dunbar, & Charles V. Pollack. (2010). Clevidipine for severe hypertension in patients with renal dysfunction: A VELOCITY trial analysis. Blood Pressure. 20(sup1). 20–25. 10 indexed citations
4.
Peacock, W. Frank, Joseph Varón, Ramin Ebrahimi, Lala M. Dunbar, & Charles V. Pollack. (2009). Clevidipine for Severe Hypertension in Acute Heart Failure: A VELOCITY Trial Analysis. Congestive Heart Failure. 16(2). 55–59. 23 indexed citations
5.
Dunbar, Lala M.. (2008). A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Therapeutics and Clinical Risk Management. Volume 4(1). 235–244. 26 indexed citations
6.
Pollack, Charles V., et al.. (2008). Clevidipine, an Intravenous Dihydropyridine Calcium Channel Blocker, Is Safe and Effective for the Treatment of Patients With Acute Severe Hypertension. Annals of Emergency Medicine. 53(3). 329–338. 68 indexed citations
7.
8.
Stryjewski, Martín E., Vivian H. Chu, William O’Riordan, et al.. (2006). Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study. Antimicrobial Agents and Chemotherapy. 50(3). 862–867. 133 indexed citations
9.
Stryjewski, Martín E., W. O'Riordan, William K. Lau, et al.. (2005). Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria. Clinical Infectious Diseases. 40(11). 1601–1607. 146 indexed citations
10.
Fogarty, Charles, et al.. (2005). Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study. BMC Infectious Diseases. 5(1). 43–43. 13 indexed citations
11.
Talan, David A., Fredrick M. Abrahamian, Gregory J. Moran, et al.. (2004). Tetanus immunity and physician compliance with tetanus prophylaxis practices among emergency department patients presenting with wounds. Annals of Emergency Medicine. 43(3). 305–314. 65 indexed citations
12.
13.
Dunbar, Lala M., Mohammed M. Khashab, James B. Kahn, et al.. (2004). Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Current Medical Research and Opinion. 20(4). 555–563. 68 indexed citations
14.
Dunbar, Lala M., Richard G. Wunderink, Michael P. Habib, et al.. (2003). High‐Dose, Short‐Course Levofloxacin for Community‐Acquired Pneumonia: A New Treatment Paradigm. Clinical Infectious Diseases. 37(6). 752–760. 250 indexed citations
15.
Dunbar, Lala M.. (2003). Current Issues in the Management of Bacterial Respiratory Tract Disease: The Challenge of Antibacterial Resistance. The American Journal of the Medical Sciences. 326(6). 360–368. 15 indexed citations
16.
Fogarty, Charles, Richard N. Greenberg, Lala M. Dunbar, et al.. (2001). Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. Clinical Therapeutics. 23(3). 425–439. 27 indexed citations
17.
Tumlin, James A., Lala M. Dunbar, Suzanne Oparil, et al.. (2000). Fenoldopam, a Dopamine Agonist, for Hypertensive Emergency: A Multicenter Randomized Trial. Academic Emergency Medicine. 7(6). 653–662. 55 indexed citations
18.
19.
Bednarczyk, Edward M., et al.. (1995). Randomized, Prospective Trial of Fenoldopam vs Sodium Nitroprusside in the Treatment of Acute Severe Hypertension. Academic Emergency Medicine. 2(11). 959–965. 50 indexed citations
20.
Dunbar, Lala M.. (1990). Emergency Room Management Of Congestive Heart Failure. Hospital Practice. 25(sup1). 7–14. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Y. Péan Breakdown of academic impact, for papers by Murray A. Abramson Breakdown of academic impact, for papers by Jeannie D. Chan Breakdown of academic impact, for papers by Alexandra Heininger Breakdown of academic impact, for papers by Luis Felipe Reyes Breakdown of academic impact, for papers by Denis Bugnon Breakdown of academic impact, for papers by Christian Eckmann Breakdown of academic impact, for papers by Daniel Curcio Breakdown of academic impact, for papers by Efthymia Giannitsioti Breakdown of academic impact, for papers by Twisha S Patel
Rankless by CCL
2026